Prediction of Postoperative Complications and Survival in Gastric Cancer Using Preoperative Blood Markers

Clinical Study on the Effect of Preoperative Serum Biomarkers on the Prognosis of Gastric Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06686966

Enrollment

3400

Registered

2024-11-13

Start date

2010-01-01

Completion date

2024-11-01

Last updated

2026-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancers

Keywords

gastric cancer, machine learning, serum biomarkers

Brief summary

Gastric cancer is one of the most common cancers worldwide, especially in East Asia. Although surgery remains the main treatment, patients may experience postoperative complications and have varying long-term survival outcomes. Early identification of high-risk patients before surgery is important for improving treatment decisions and patient management. This study aims to develop a prediction model based on routinely available preoperative blood test results and clinical characteristics to estimate the risk of postoperative complications and long-term survival in patients with gastric cancer. The model will be developed and validated using data from multiple medical centers. By using easily accessible clinical information, this study seeks to provide a practical tool to help clinicians better assess patient risk before surgery, support personalized treatment planning, and improve overall patient outcomes.

Interventions

DIAGNOSTIC_TESTgastric cancer

be diagnosed as gastric cancer

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients aged ≥18 years; * patients diagnosed with gastric cancer by pathological biopsy before surgery; * patients without chemotherapy, radiotherapy, targeted and immunotherapy before enrolment; * willing to participate in this study and sign the informed consent; * complete clinical data.

Exclusion criteria

* patients with other primary malignant tumours other than gastric cancer; * patients with systemic diseases such as severe cardiopulmonary insufficiency that affect the choice of treatment plan; * patients who are not suitable for enrolment as assessed by the investigator; * incomplete clinical data.

Design outcomes

Primary

Measure	Time frame	Description
the incidence of gastric cancer	From 18 years old until the developing gastric cancer, through study completion, an average of 5 year.	the diagnosis time of gastric cancer

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026